Adaptive Biotechnologies (ADPT) Current Leases (2020 - 2026)

Adaptive Biotechnologies has reported Current Leases for 7 years, with the latest figure at $8.5 million in Q1 2026.

• Quarterly Current Leases fell 18.63% year-over-year to $8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.5 million (down 18.63% YoY) and the FY2025 annual result came in at $8.9 million, down 12.88% from the prior year.
• Current Leases retreated to $8.5 million in Q1 2026 per ADPT's latest filing, from $8.9 million in the prior quarter.
• Over five years, Current Leases peaked at $10.5 million in Q1 2025 and troughed at $8.5 million in Q1 2026.
• A 5-year average of $9.4 million and a median of $9.4 million in 2023 frame the typical range for Current Leases.
• The sharpest annual moves came in 2022 and 2026: Current Leases surged 98.35% in 2022, then fell 18.63% in 2026.
• Over 5 years, Current Leases stood at $9.2 million in 2022, then advanced by 1.67% to $9.4 million in 2023, then rose by 9.11% to $10.2 million in 2024, then slipped by 12.88% to $8.9 million in 2025, then fell by 4.56% to $8.5 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $8.5 million, $8.9 million, and $9.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.